AbbVie recently launched the latest action in its long-running US IP battles with producers of biosimilar versions of its blockbuster drug, adalimumab (marketed as Humira). Although the company is best-known for the successful assertion of large patent estates, it is now accusing Icelandic biotech Alvotech of misappropriating its Humira-related trade secrets. Goodwin IP Litigation partner Robert Cerwinski points out that these risks are growing. Read the Intellectual Asset Management article here.
In The Press March 30, 2021